Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Autoimmune Disorders

  Free Subscription


Articles published in J Neuroimmunol

Retrieve available abstracts of 273 articles:
HTML format
Text format



Single Articles


    July 2018
  1. NAKAMURA R, Makino T, Hanada T, Terakawa M, et al
    Heterogeneity of auto-antibodies against nAChR in myasthenic serum and their pathogenic roles in experimental autoimmune myasthenia gravis.
    J Neuroimmunol. 2018;320:64-75.
    PubMed     Text format     Abstract available


  2. KARAMPOOR S, Zahednasab H, Etemadifar M, Keyvani H, et al
    The levels of soluble forms of CD21 and CD83 in multiple sclerosis.
    J Neuroimmunol. 2018;320:11-14.
    PubMed     Text format     Abstract available


    June 2018
  3. SERAFINI B, Zandee S, Rosicarelli B, Scorsi E, et al
    Epstein-Barr virus-associated immune reconstitution inflammatory syndrome as possible cause of fulminant multiple sclerosis relapse after natalizumab interruption.
    J Neuroimmunol. 2018;319:9-12.
    PubMed     Text format    


  4. SERIZAWA K, Tomizawa-Shinohara H, Magi M, Yogo K, et al
    Anti-IL-6 receptor antibody improves pain symptoms in mice with experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;319:71-79.
    PubMed     Text format     Abstract available


  5. TIJERO B, Del Pino R, Perez-Concha T, Acera MA, et al
    Seronegative and seropositive autoimmune autonomic ganglionopathy (AAG): Same clinical picture, same response to immunotherapy.
    J Neuroimmunol. 2018;319:68-70.
    PubMed     Text format     Abstract available


  6. YOSHIKURA N, Kimura A, Fukata M, Fukata Y, et al
    Long-term clinical follow-up of a patient with non-paraneoplastic cerebellar ataxia associated with anti-mGluR1 autoantibodies.
    J Neuroimmunol. 2018;319:63-67.
    PubMed     Text format     Abstract available


  7. HIRATSUKA D, Furube E, Taguchi K, Tanaka M, et al
    Remyelination in the medulla oblongata of adult mouse brain during experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;319:41-54.
    PubMed     Text format     Abstract available


  8. AKAISHI T, Takahashi T, Nakashima I
    Peripheral blood monocyte count at onset may affect the prognosis in multiple sclerosis.
    J Neuroimmunol. 2018;319:37-40.
    PubMed     Text format     Abstract available


    May 2018
  9. CHU F, Shi M, Zheng C, Shen D, et al
    The roles of macrophages and microglia in multiple sclerosis and experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;318:1-7.
    PubMed     Text format     Abstract available


    April 2018
  10. CASTANEDA-MORENO VA, De la Cruz-Mosso U, Torres-Carrillo N, Macias-Islas MA, et al
    MIF functional polymorphisms (-794 CATT5-8 and -173 G>C) are associated with MIF serum levels, severity and progression in male multiple sclerosis from western Mexican population.
    J Neuroimmunol. 2018 Apr 10. pii: S0165-5728(17)30593.
    PubMed     Text format     Abstract available


  11. YAN J, Winterford CM, Catts VS, Pat BK, et al
    Increased constitutive activation of NF-kappaB p65 (RelA) in peripheral blood cells of patients with progressive multiple sclerosis.
    J Neuroimmunol. 2018 Apr 6. pii: S0165-5728(17)30536.
    PubMed     Text format     Abstract available


  12. LI J, Qiu D, Chen Z, Du W, et al
    miR-548k regulates CXCL13 expression in myasthenia gravis patients with thymic hyperplasia and in Jurkat cells.
    J Neuroimmunol. 2018 Apr 4. pii: S0165-5728(18)30166.
    PubMed     Text format     Abstract available


    March 2018
  13. ZAGORITI Z, Lagoumintzis G, Perroni G, Papathanasiou G, et al
    Evidence for association of STAT4 and IL12RB2 variants with Myasthenia gravis susceptibility: What is the effect on gene expression in thymus?
    J Neuroimmunol. 2018 Mar 17. pii: S0165-5728(17)30559.
    PubMed     Text format     Abstract available


  14. ALLENDER E, Deol H, Schram S, Maheras KJ, et al
    Neuregulin1 modulation of experimental autoimmune encephalomyelitis (EAE).
    J Neuroimmunol. 2018 Mar 10. pii: S0165-5728(17)30466.
    PubMed     Text format     Abstract available


  15. PAUNOVIC V, Petrovic IV, Milenkovic M, Janjetovic K, et al
    Autophagy-independent increase of ATG5 expression in T cells of multiple sclerosis patients.
    J Neuroimmunol. 2018 Mar 5. pii: S0165-5728(17)30538.
    PubMed     Text format     Abstract available


  16. SMITH PA, Schmid C, Zurbruegg S, Jivkov M, et al
    Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis.
    J Neuroimmunol. 2018 Mar 3. pii: S0165-5728(17)30519.
    PubMed     Text format     Abstract available


  17. ASHTARI F, Esmaeil N, Mansourian M, Poursafa P, et al
    An 8-year study of people with multiple sclerosis in Isfahan, Iran: Association between environmental air pollutants and severity of disease.
    J Neuroimmunol. 2018 Mar 2. pii: S0165-5728(18)30019.
    PubMed     Text format     Abstract available


    February 2018
  18. MONTEIRO A, Cruto C, Rosado P, Martinho A, et al
    Characterization of circulating gamma-delta T cells in relapsing vs remission multiple sclerosis.
    J Neuroimmunol. 2018 Feb 24. pii: S0165-5728(17)30533.
    PubMed     Text format     Abstract available


  19. BARBOUR M, Wood R, Hridi SU, Wilson C, et al
    The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels.
    J Neuroimmunol. 2018 Feb 24. pii: S0165-5728(17)30457.
    PubMed     Text format     Abstract available


  20. ROZMILOWSKA IM, Adamczyk-Sowa MH
    What is the role of interleukin 33 and ST2 receptor in myasthenia gravis?
    J Neuroimmunol. 2018;315:50-57.
    PubMed     Text format    


  21. KUHN I, Rogosch T, Schindler TI, Tackenberg B, et al
    Serum titers of autoantibodies against alpha-synuclein and tau in child- and adulthood.
    J Neuroimmunol. 2018;315:33-39.
    PubMed     Text format     Abstract available


  22. GEORGE JD, Kim E, Spain R, Bourdette D, et al
    Effects of lipoic acid on migration of human B cells and monocyte-enriched peripheral blood mononuclear cells in relapsing remitting multiple sclerosis.
    J Neuroimmunol. 2018;315:24-27.
    PubMed     Text format     Abstract available


  23. IP PP, Chung CY, Chang CC, Lee YF, et al
    Differentiation of remitting neuromyelitis optica spectrum disorders from multiple sclerosis by integrating parameters from serum proteins and lymphocyte subsets.
    J Neuroimmunol. 2018 Feb 8. pii: S0165-5728(17)30498.
    PubMed     Text format     Abstract available


    January 2018
  24. LIU C, Liu H, Jin H, Yue X, et al
    Cholinergic imbalance in lumbar spinal cord of a rat model of multiple sclerosis.
    J Neuroimmunol. 2018 Jan 31. pii: S0165-5728(17)30560.
    PubMed     Text format     Abstract available


  25. HOR JY, Lim TT, Cheng MC, Chia YK, et al
    Thymoma-associated myasthenia gravis and LGI1-encephalitis, with nephrotic syndrome post-thymectomy.
    J Neuroimmunol. 2018 Jan 30. pii: S0165-5728(17)30491.
    PubMed     Text format     Abstract available


  26. RAHMAN MI, Jahan I, Khalid MM, Jahan I, et al
    CD1A and CD1E gene polymorphisms are not associated with susceptibility to Guillain-Barre syndrome in the Bangladeshi population.
    J Neuroimmunol. 2018;314:8-12.
    PubMed     Text format     Abstract available


  27. MEYER SAUTEUR PM, Huizinga R, Tio-Gillen AP, Drenthen J, et al
    Intrathecal antibody responses to GalC in Guillain-Barre syndrome triggered by Mycoplasma pneumoniae.
    J Neuroimmunol. 2018;314:13-16.
    PubMed     Text format     Abstract available


  28. LOSHAJ-SHALA A, Colzani M, Brezovska K, Poceva Panovska A, et al
    Immunoproteomic identification of antigenic candidate Campylobacter jejuni and human peripheral nerve proteins involved in Guillain-Barre syndrome.
    J Neuroimmunol. 2018 Jan 9. pii: S0165-5728(17)30422.
    PubMed     Text format     Abstract available


  29. VOGRIG A, Pauletto G, Belgrado E, Pegolo E, et al
    Effect of thymectomy on refractory autoimmune status epilepticus.
    J Neuroimmunol. 2018 Jan 9. pii: S0165-5728(17)30485.
    PubMed     Text format     Abstract available


  30. LV J, Li L, Li W, Ji K, et al
    Role of the chemokine receptors CXCR3, CXCR4 and CCR7 in the intramuscular recruitment of plasmacytoid dendritic cells in dermatomyositis.
    J Neuroimmunol. 2018 Jan 9. pii: S0165-5728(18)30015.
    PubMed     Text format     Abstract available


  31. BAULINA N, Kulakova O, Kiselev I, Osmak G, et al
    Immune-related miRNA expression patterns in peripheral blood mononuclear cells differ in multiple sclerosis relapse and remission.
    J Neuroimmunol. 2018 Jan 5. pii: S0165-5728(17)30447.
    PubMed     Text format     Abstract available


  32. MASUDA H, Mori M, Umehara K, Furihata T, et al
    Soluble CD40 ligand disrupts the blood-brain barrier and exacerbates inflammation in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018 Jan 3. pii: S0165-5728(17)30562.
    PubMed     Text format     Abstract available


  33. OZKUL C, Guclu-Gunduz A, Irkec C, Fidan I, et al
    Effect of combined exercise training on serum brain-derived neurotrophic factor, suppressors of cytokine signaling 1 and 3 in patients with multiple sclerosis.
    J Neuroimmunol. 2018 Jan 3. pii: S0165-5728(17)30484.
    PubMed     Text format     Abstract available


    December 2017
  34. DETRICK B, Gangaputra S, Palsgrove DN, Heaney CD, et al
    Elevated serum levels of IL-6 and CXCL9 in autoimmune retinopathy (AIR) patients.
    J Neuroimmunol. 2017 Dec 29. pii: S0165-5728(17)30269.
    PubMed     Text format     Abstract available


  35. IMITOLA J, Rasouli J, Watanabe F, Mahajan K, et al
    Elevated expression of granulocyte-macrophage colony-stimulating factor receptor in multiple sclerosis lesions.
    J Neuroimmunol. 2017 Dec 22. pii: S0165-5728(17)30304.
    PubMed     Text format     Abstract available


  36. ROLLA S, De Mercanti SF, Bardina V, Horakova D, et al
    Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses.
    J Neuroimmunol. 2017;313:89-91.
    PubMed     Text format     Abstract available


  37. BHAT R, Mahapatra S, Axtell RC, Steinman L, et al
    Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine.
    J Neuroimmunol. 2017;313:77-81.
    PubMed     Text format     Abstract available


  38. TAYLOR JM
    Tissue resident macrophages are sufficient for demyelination during peripheral nerve myelin induced experimental autoimmune neuritis?
    J Neuroimmunol. 2017;313:69-76.
    PubMed     Text format     Abstract available


  39. LI R, Sun X, Shu Y, Wang Y, et al
    Serum CCL20 and its association with SIRT1 activity in multiple sclerosis patients.
    J Neuroimmunol. 2017;313:56-60.
    PubMed     Text format     Abstract available


  40. GILLI F, Royce DB, DiSano KD, Pachner AR, et al
    Pegylated interferon beta in the treatment of the Theiler's murine encephalomyelitis virus mouse model of multiple sclerosis.
    J Neuroimmunol. 2017;313:34-40.
    PubMed     Text format     Abstract available


  41. LIU J, Lian Z, Chen H, Shi Z, et al
    Associations between tumor necrosis factor-alpha gene polymorphisms and the risk of Guillain-Barre syndrome and its subtypes: A systematic review and meta-analysis.
    J Neuroimmunol. 2017;313:25-33.
    PubMed     Text format     Abstract available


  42. AKAISHI T, Kaneko K, Himori N, Takeshita T, et al
    Subclinical retinal atrophy in the unaffected fellow eyes of multiple sclerosis and neuromyelitis optica.
    J Neuroimmunol. 2017;313:10-15.
    PubMed     Text format     Abstract available


  43. GLENN JD, Xue P, Whartenby KA
    Gemcitabine directly inhibits effector CD4 T cell activation and prevents experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2017 Dec 8. pii: S0165-5728(17)30303.
    PubMed     Text format     Abstract available


  44. BANSI J, Koliamitra C, Bloch W, Joisten N, et al
    Persons with secondary progressive and relapsing remitting multiple sclerosis reveal different responses of tryptophan metabolism to acute endurance exercise and training.
    J Neuroimmunol. 2017 Dec 6. pii: S0165-5728(17)30420.
    PubMed     Text format     Abstract available


    November 2017
  45. KIM MJ, Lim JY, Park SA, Park SI, et al
    Effective combination of methylprednisolone and interferon beta-secreting mesenchymal stem cells in a model of multiple sclerosis.
    J Neuroimmunol. 2017 Nov 29. pii: S0165-5728(17)30134.
    PubMed     Text format     Abstract available


  46. MONTELEONE F, Nicoletti CG, Stampanoni Bassi M, Iezzi E, et al
    Nerve growth factor is elevated in the CSF of patients with multiple sclerosis and central neuropathic pain.
    J Neuroimmunol. 2017 Nov 20. pii: S0165-5728(17)30179.
    PubMed     Text format     Abstract available


  47. YOSHIKURA N, Kimura A, Hayashi Y, Inuzuka T, et al
    Corrigendum to Anti-C1q autoantibodies in patients with neuromyelitis optica spectrum disorders" [J. Neuroimmunol. 310. (2017) 150-157].
    J Neuroimmunol. 2017;312:66.
    PubMed     Text format    


  48. WANG Y, Zhang W, Yin J, Lu Q, et al
    Anti-N-methyl-d-aspartate receptor encephalitis in children of Central South China: Clinical features, treatment, influencing factors, and outcomes.
    J Neuroimmunol. 2017;312:59-65.
    PubMed     Text format     Abstract available


  49. HESSELMARK E, Bejerot S
    Biomarkers for diagnosis of Pediatric Acute Neuropsychiatric Syndrome (PANS) - Sensitivity and specificity of the Cunningham Panel.
    J Neuroimmunol. 2017;312:31-37.
    PubMed     Text format     Abstract available


  50. SVEINSSON O, Granqvist M, Forslin Y, Blennow K, et al
    Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis.
    J Neuroimmunol. 2017;312:15-18.
    PubMed     Text format     Abstract available


  51. ROLF L, Muris AH, Theunissen R, Hupperts R, et al
    Vitamin D3 supplementation and the IL-2/IL-2R pathway in multiple sclerosis: Attenuation of progressive disturbances?
    J Neuroimmunol. 2017 Nov 10. pii: S0165-5728(17)30208.
    PubMed     Text format     Abstract available


  52. MAZDEH M, Moradi N, Khoshroo E, Shayesteh Z, et al
    Down-regulation of TYK2, CBLB and LMP7 genes expression in relapsing-remitting multiple sclerosis patients treated with interferon-beta.
    J Neuroimmunol. 2017 Nov 8. pii: S0165-5728(17)30405.
    PubMed     Text format     Abstract available


    October 2017
  53. LIU W, Zhu M, Yu Z, Yin D, et al
    Therapeutic effects of diosgenin in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2017 Oct 31. pii: S0165-5728(17)30191.
    PubMed     Text format     Abstract available


  54. PALTERER B, Brugnolo F, Sieni E, Barilaro A, et al
    Neuromyelitis optica, atypical hemophagocytic lymphohistiocytosis and heterozygous perforin A91V mutation.
    J Neuroimmunol. 2017;311:10-13.
    PubMed     Text format     Abstract available


  55. LEI HW, Wang JY, Dang QJ, Yang F, et al
    Neuropsychiatric involvement in lupus is associated with the Nogo-a/NgR1 pathway.
    J Neuroimmunol. 2017;311:22-28.
    PubMed     Text format     Abstract available


  56. HUANG ZL, Pandya D, Banta DK, Ansari MS, et al
    Cyclophilin inhibitor NIM811 ameliorates experimental allergic encephalomyelitis.
    J Neuroimmunol. 2017;311:40-48.
    PubMed     Text format     Abstract available


    September 2017
  57. FERNANDEZ HURST N, Zanetti SR, Baez NS, Bibolini MJ, et al
    Diazepam treatment reduces inflammatory cells and mediators in the central nervous system of rats with experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2017 Sep 30. pii: S0165-5728(17)30297.
    PubMed     Text format     Abstract available


  58. MERKER M, Eichler S, Herrmann AM, Wiendl H, et al
    Rivaroxaban ameliorates disease course in an animal model of multiple sclerosis.
    J Neuroimmunol. 2017 Sep 21. pii: S1521-6616(17)30639.
    PubMed     Text format     Abstract available


  59. BADIHIAN S, Manouchehri N, Badihian N
    More evidence is needed to show any role of cytomegalovisrus and varicella zoster virus in pathogenesis of multiple sclerosis.
    J Neuroimmunol. 2017 Sep 18. pii: S0165-5728(17)30401.
    PubMed     Text format    


  60. VILLANI S, Zanotta N, Ambrogi F, Comar M, et al
    Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis.
    J Neuroimmunol. 2017;310:91-96.
    PubMed     Text format     Abstract available


  61. CHANGYALEKET B, Deliu Z, Chignalia AZ, Feinstein DL, et al
    Heparanase: Potential roles in multiple sclerosis.
    J Neuroimmunol. 2017;310:72-81.
    PubMed     Text format     Abstract available


  62. JAHAN I, Ahammad RU, Farzana KS, Khalid MM, et al
    Tumor necrosis factor-alpha -863C/A polymorphism is associated with Guillain-Barre syndrome in Bangladesh.
    J Neuroimmunol. 2017;310:46-50.
    PubMed     Text format     Abstract available


  63. NIELSEN BR, Ratzer R, Bornsen L, von Essen MR, et al
    Characterization of naive, memory and effector T cells in progressive multiple sclerosis.
    J Neuroimmunol. 2017;310:17-25.
    PubMed     Text format     Abstract available


  64. HAITAO R, Huiqin L, Tao Q, Xunzhe Y, et al
    Autoimmune encephalitis associated with vitiligo?
    J Neuroimmunol. 2017;310:14-16.
    PubMed     Text format     Abstract available


  65. DELGADO-GARCIA G, Corona-Vazquez T
    IgG4-related disease and IgG4-mediated neurological autoimmune disorders: One and the same?
    J Neuroimmunol. 2017;310:129-130.
    PubMed     Text format    


  66. PENN M, Mausner-Fainberg K, Golan M, Karni A, et al
    High serum levels of BMP-2 correlate with BMP-4 and BMP-5 levels and induce reduced neuronal phenotype in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2017;310:120-128.
    PubMed     Text format     Abstract available


  67. BENEDEK G, Zhang J, Nguyen H, Kent G, et al
    Estrogen protection against EAE modulates the microbiota and mucosal-associated regulatory cells.
    J Neuroimmunol. 2017;310:51-59.
    PubMed     Text format     Abstract available


  68. ZHU DS, Yu L, Li M, Han L, et al
    High serum creatinine is associated with reduction of vision impaired in patients with NMOSD.
    J Neuroimmunol. 2017;310:32-37.
    PubMed     Text format     Abstract available


  69. WANG J, Yang C, Zhao Q, Zhu Z, et al
    Microglia activation induced by serum of SLE patients.
    J Neuroimmunol. 2017;310:135-142.
    PubMed     Text format     Abstract available


  70. LINDSEY JW
    Antibodies to the Epstein-Barr virus proteins BFRF3 and BRRF2 cross-react with human proteins.
    J Neuroimmunol. 2017;310:131-134.
    PubMed     Text format     Abstract available


  71. ALVARENGA MP, Fernandez O, Leyva L, Campanella L, et al
    The HLA DRB1*03:01 allele is associated with NMO regardless of the NMO-IgG status in Brazilian patients from Rio de Janeiro.
    J Neuroimmunol. 2017;310:1-7.
    PubMed     Text format     Abstract available


  72. VERCELLINO M, Trebini C, Capello E, Mancardi GL, et al
    Inflammatory responses in Multiple Sclerosis normal-appearing white matter and in non-immune mediated neurological conditions with wallerian axonal degeneration: A comparative study.
    J Neuroimmunol. 2017 Sep 8. pii: S0165-5728(17)30131.
    PubMed     Text format     Abstract available


  73. LAZARIDIS K, Dalianoudis I, Baltatzidi V, Tzartos SJ, et al
    Specific removal of autoantibodies by extracorporeal immunoadsorption ameliorates experimental autoimmune myasthenia gravis.
    J Neuroimmunol. 2017 Sep 6. pii: S0165-5728(17)30332.
    PubMed     Text format     Abstract available


    August 2017
  74. YESHOKUMAR AK, Gordon-Lipkin E, Arenivas A, Cohen J, et al
    Neurobehavioral outcomes in autoimmune encephalitis.
    J Neuroimmunol. 2017 Aug 31. pii: S0165-5728(17)30274.
    PubMed     Text format     Abstract available


  75. ALVAREZ BRAVO G, Yusta Izquierdo A, Carvalho Monteiro G, Sanchez I, et al
    Cerebellopathy secondary to anti-peroxidase antibody-mediated toxicity. A special case of Hashimoto encephalopathy.
    J Neuroimmunol. 2017 Aug 19. pii: S0165-5728(17)30265.
    PubMed     Text format     Abstract available


  76. LIU RT, Zhang P, Yang CL, Pang Y, et al
    ONX-0914, a selective inhibitor of immunoproteasome, ameliorates experimental autoimmune myasthenia gravis by modulating humoral response.
    J Neuroimmunol. 2017 Aug 18. pii: S0165-5728(17)30182.
    PubMed     Text format     Abstract available


  77. LISAK RP, Nedelkoska L, Benjamins JA, Schalk D, et al
    B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro.
    J Neuroimmunol. 2017;309:88-99.
    PubMed     Text format     Abstract available


  78. WALLWITZ U, Brock S, Schunck A, Wildemann B, et al
    From dizziness to severe ataxia and dysarthria: New cases of anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia suggest a broad clinical spectrum.
    J Neuroimmunol. 2017;309:77-81.
    PubMed     Text format     Abstract available


  79. PITAROKOILI K, Kohle F, Motte J, Fatoba O, et al
    Anti-inflammatory and immunomodulatory potential of human immunoglobulin applied intrathecally in Lewis rat experimental autoimmune neuritis.
    J Neuroimmunol. 2017;309:58-67.
    PubMed     Text format     Abstract available


  80. DEMARSHALL C, Goldwaser EL, Sarkar A, Godsey GA, et al
    Autoantibodies as diagnostic biomarkers for the detection and subtyping of multiple sclerosis.
    J Neuroimmunol. 2017;309:51-57.
    PubMed     Text format     Abstract available


  81. CAROTENUTO A, Scalia G, Ausiello F, Moccia M, et al
    CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients.
    J Neuroimmunol. 2017;309:47-50.
    PubMed     Text format     Abstract available


  82. MATHEY EK, Garg N, Park SB, Nguyen T, et al
    Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies.
    J Neuroimmunol. 2017;309:41-46.
    PubMed     Text format     Abstract available


  83. KARAMPOOR S, Zahednasab H, Ramagopalan S, Mehrpour M, et al
    Cytomegalovirus and varicella zoster virus seropositivity of Iranian patients with multiple sclerosis: A population-based study.
    J Neuroimmunol. 2017;309:4-6.
    PubMed     Text format     Abstract available


  84. BETTENCOURT A, Boleixa D, Guimaraes AL, Leal B, et al
    The vitamin D receptor gene FokI polymorphism and Multiple Sclerosis in a Northern Portuguese population.
    J Neuroimmunol. 2017;309:34-37.
    PubMed     Text format     Abstract available


  85. PIERI M, Storto M, Pignalosa S, Zenobi R, et al
    KFLC Index utility in multiple sclerosis diagnosis: Further confirmation.
    J Neuroimmunol. 2017;309:31-33.
    PubMed     Text format     Abstract available


  86. LI X, Lin J, Pan S, Weng Y, et al
    Suspected bacterial meningomyelitis: The first presenting clinical feature of neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2017;309:68-71.
    PubMed     Text format     Abstract available


  87. KON T, Ueno T, Suzuki C, Nunomura J, et al
    Aquaporin-4 antibody positive neuromyelitis optica spectrum disorder associated with esophageal cancer.
    J Neuroimmunol. 2017;309:38-40.
    PubMed     Text format     Abstract available


  88. LIU J, Shi Z, Lian Z, Chen H, et al
    Association of CD58 gene polymorphisms with NMO spectrum disorders in a Han Chinese population.
    J Neuroimmunol. 2017;309:23-30.
    PubMed     Text format     Abstract available


  89. HENDRICKX DAE, van Eden CG, Schuurman KG, Hamann J, et al
    Staining of HLA-DR, Iba1 and CD68 in human microglia reveals partially overlapping expression depending on cellular morphology and pathology.
    J Neuroimmunol. 2017;309:12-22.
    PubMed     Text format     Abstract available


  90. SUCHDEV K, Razmjou S, Venkatachalam P, Khan OA, et al
    Late onset neuromyelitis optica mimicking an acute stroke in an elderly patient.
    J Neuroimmunol. 2017;309:1-3.
    PubMed     Text format     Abstract available


  91. AHMAD SF, Ansari MA, Nadeem A, Bakheet SA, et al
    Adenosine A2A receptor signaling affects IL-21/IL-22 cytokines and GATA3/T-bet transcription factor expression in CD4+ T cells from a BTBR T+ Itpr3tf/J mouse model of autism.
    J Neuroimmunol. 2017 Aug 9. pii: S0165-5728(17)30253.
    PubMed     Text format     Abstract available


  92. WILDNER P, Selmaj KW
    Multiple sclerosis: Skin-induced antigen-specific immune tolerance.
    J Neuroimmunol. 2017 Aug 2. pii: S0165-5728(17)30263.
    PubMed     Text format     Abstract available


    July 2017
  93. YOSHIKURA N, Kimura A, Hayashi Y, Inuzuka T, et al
    Anti-C1q autoantibodies in patients with neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2017 Jul 19. pii: S0165-5728(17)30144.
    PubMed     Text format     Abstract available


    June 2017
  94. LIU G, Zhang F, Hu Y, Jiang Y, et al
    Multiple sclerosis risk pathways differ in Caucasian and Chinese populations.
    J Neuroimmunol. 2017;307:63-68.
    PubMed     Text format     Abstract available


  95. ASMAIL A, Kesler A, Drory VE, Kolb H, et al
    Effect of ethnic origin and gender on the clinical manifestations of myasthenia gravis among the Jewish population in Israel.
    J Neuroimmunol. 2017;307:47-52.
    PubMed     Text format     Abstract available


  96. FERNANDO KTM, James M
    Early predictors of rapidly evolving multiple sclerosis: A case report.
    J Neuroimmunol. 2017;307:42-46.
    PubMed     Text format     Abstract available


  97. ZAHOOR I, Haq E
    Multiple sclerosis in India: Iceberg or volcano.
    J Neuroimmunol. 2017;307:27-30.
    PubMed     Text format     Abstract available


  98. SAUER EL, Trifilieff E, Greer JM
    Predicting the effects of potentially therapeutic modified peptides on polyclonal T cell populations in a mouse model of multiple sclerosis.
    J Neuroimmunol. 2017;307:18-26.
    PubMed     Text format     Abstract available


  99. SERAFINI B, Scorsi E, Rosicarelli B, Rigau V, et al
    Massive intracerebral Epstein-Barr virus reactivation in lethal multiple sclerosis relapse after natalizumab withdrawal.
    J Neuroimmunol. 2017;307:14-17.
    PubMed     Text format     Abstract available


  100. KINOSHITA M, Daifu M, Tanaka K, Tanaka M, et al
    Prognostic value of oligoclonal IgG bands in Japanese clinically isolated syndrome converting to clinically definite multiple sclerosis.
    J Neuroimmunol. 2017;307:1-6.
    PubMed     Text format     Abstract available


  101. BARROS PO, Dias ASO, Kasahara TM, Ornelas AMM, et al
    Expansion of IL-6+ Th17-like cells expressing TLRs correlates with microbial translocation and neurological disabilities in NMOSD patients.
    J Neuroimmunol. 2017;307:82-90.
    PubMed     Text format     Abstract available


    May 2017
  102. JING S, Song Y, Song J, Pang S, et al
    Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis.
    J Neuroimmunol. 2017 May 30. pii: S0165-5728(17)30074.
    PubMed     Text format     Abstract available


  103. AKAISHI T, Nakashima I, Mugikura S, Aoki M, et al
    Whole brain and grey matter volume of Japanese patients with multiple sclerosis.
    J Neuroimmunol. 2017;306:68-75.
    PubMed     Text format     Abstract available


  104. SISAY S, Lopez-Lozano L, Mickunas M, Quiroga-Fernandez A, et al
    Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS.
    J Neuroimmunol. 2017;306:40-45.
    PubMed     Text format     Abstract available


  105. CONSTANTINESCU R, Krysl D, Andren K, Asztely F, et al
    Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies.
    J Neuroimmunol. 2017;306:25-30.
    PubMed     Text format     Abstract available


  106. BERMUDEZ-MORALES VH, Fierros G, Lopez RL, Martinez-Nava G, et al
    Vitamin D receptor gene polymorphisms are associated with multiple sclerosis in Mexican adults.
    J Neuroimmunol. 2017;306:20-24.
    PubMed     Text format     Abstract available


  107. RAMAKRISHNAN V, Akram Husain RS, Ahmed SS
    Genetic predisposition of IL-10 promoter polymorphisms with risk of multiple sclerosis: A meta-analysis.
    J Neuroimmunol. 2017;306:11-18.
    PubMed     Text format     Abstract available


  108. SELMAJ I, Mycko MP, Raine CS, Selmaj KW, et al
    The role of exosomes in CNS inflammation and their involvement in multiple sclerosis.
    J Neuroimmunol. 2017;306:1-10.
    PubMed     Text format     Abstract available


    April 2017
  109. RAIBAGKAR P, Ferry JA, Stone JH
    Is MuSK myasthenia gravis linked to IgG4-related disease?
    J Neuroimmunol. 2017;305:82-83.
    PubMed     Text format     Abstract available


  110. MORIGUCHI K, Miyamoto K, Kusunoki S
    4-Aminopyridine ameliorates experimental autoimmune neuritis in Lewis rats.
    J Neuroimmunol. 2017;305:72-74.
    PubMed     Text format     Abstract available


  111. JACOB S, Al-Kandari A, Alroughani R, Al-Temaimi R, et al
    Assessment of plasma biomarkers for their association with Multiple Sclerosis progression.
    J Neuroimmunol. 2017;305:5-8.
    PubMed     Text format     Abstract available


  112. BUTTARI F, Zagaglia S, Marciano L, Albanese M, et al
    TRPV1 polymorphisms and risk of interferon beta-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2017;305:172-174.
    PubMed     Text format     Abstract available


  113. BROWN MP, Hissaria P, Hsieh AH, Kneebone C, et al
    Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy.
    J Neuroimmunol. 2017;305:16-18.
    PubMed     Text format     Abstract available


  114. ZHANG M, Liu RT, Zhang P, Zhang N, et al
    Parthenolide inhibits the initiation of experimental autoimmune neuritis.
    J Neuroimmunol. 2017;305:154-161.
    PubMed     Text format     Abstract available


  115. ADAMCZYK-SOWA M, Bieszczad-Bedrejczuk E, Galiniak S, Rozmilowska I, et al
    Oxidative modifications of blood serum proteins in myasthenia gravis.
    J Neuroimmunol. 2017;305:145-153.
    PubMed     Text format     Abstract available


  116. MIFFLIN KA, Frieser E, Benson C, Baker G, et al
    Voluntary wheel running differentially affects disease outcomes in male and female mice with experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2017;305:135-144.
    PubMed     Text format     Abstract available


  117. MUTO M, Mori M, Liu J, Uzawa A, et al
    Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity.
    J Neuroimmunol. 2017;305:131-134.
    PubMed     Text format     Abstract available


  118. MASUDA H, Mori M, Uchida T, Uzawa A, et al
    Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2017;305:102-107.
    PubMed     Text format     Abstract available


  119. WANG Q, Xing C, Hao Y, Shi Q, et al
    Memory B cells in Guillain-Barre syndrome.
    J Neuroimmunol. 2017;305:1-4.
    PubMed     Text format     Abstract available


  120. AGLIARDI C, Guerini FR, Zanzottera M, Bolognesi E, et al
    Vitamin D-binding protein gene polymorphisms are not associated with MS risk in an Italian cohort.
    J Neuroimmunol. 2017;305:92-95.
    PubMed     Text format     Abstract available


  121. DENG B, Liu XN, Li X, Zhang X, et al
    Raised cerebrospinal fluid BAFF and APRIL levels in anti-N-methyl-d-aspartate receptor encephalitis: Correlation with clinical outcome.
    J Neuroimmunol. 2017;305:84-91.
    PubMed     Text format     Abstract available


  122. BENEDEK G, Zhang J, Nguyen H, Kent G, et al
    Novel feedback loop between M2 macrophages/microglia and regulatory B cells in estrogen-protected EAE mice.
    J Neuroimmunol. 2017;305:59-67.
    PubMed     Text format     Abstract available


  123. ZHOU L, Huang Y, Li H, Fan J, et al
    MOG-antibody associated demyelinating disease of the CNS: A clinical and pathological study in Chinese Han patients.
    J Neuroimmunol. 2017;305:19-28.
    PubMed     Text format     Abstract available


  124. SCOTT TF
    Understanding the impact of relapses in the overall course of MS; refinement of the 2 stage natural history model.
    J Neuroimmunol. 2017;305:162-166.
    PubMed     Text format     Abstract available


  125. PAWLAK-ADAMSKA E, Nowak O, Karabon L, Pokryszko-Dragan A, et al
    PD-1 gene polymorphic variation is linked with first symptom of disease and severity of relapsing-remitting form of MS.
    J Neuroimmunol. 2017;305:115-127.
    PubMed     Text format     Abstract available


  126. KIMURA A, Takemura M, Saito K, Serrero G, et al
    Increased cerebrospinal fluid progranulin correlates with interleukin-6 in the acute phase of neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2017;305:175-181.
    PubMed     Text format     Abstract available


    February 2017
  127. PANT AB, Wang Y, Mielcarz DW, Kasper EJ, et al
    Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment.
    J Neuroimmunol. 2017;303:22-30.
    PubMed     Text format     Abstract available


  128. LAZARIDIS K, Baltatzidi V, Trakas N, Koutroumpi E, et al
    Characterization of a reproducible rat EAMG model induced with various human acetylcholine receptor domains.
    J Neuroimmunol. 2017;303:13-21.
    PubMed     Text format     Abstract available


  129. WARNECKE A, Musunuri S, N'diaye M, Sandalova T, et al
    Nitration of MOG diminishes its encephalitogenicity depending on MHC haplotype.
    J Neuroimmunol. 2017;303:1-12.
    PubMed     Text format     Abstract available


  130. DEPAULA-SILVA AB, Hanak TJ, Libbey JE, Fujinami RS, et al
    Theiler's murine encephalomyelitis virus infection of SJL/J and C57BL/6J mice: Models for multiple sclerosis and epilepsy.
    J Neuroimmunol. 2017 Feb 12. pii: S0165-5728(16)30480.
    PubMed     Text format     Abstract available


    January 2017
  131. ZHANGBAO J, Zhou L, Li X, Cai T, et al
    The clinical characteristics of AQP4 antibody positive NMO/SD in a large cohort of Chinese Han patients.
    J Neuroimmunol. 2017;302:49-55.
    PubMed     Text format     Abstract available


  132. NAKAHARA K, Nakane S, Nakajima M, Yamashita S, et al
    Effect of thymectomy for thymic atrophy in myasthenia gravis: A retrospective study on 93 patients.
    J Neuroimmunol. 2017 Jan 12. pii: S0165-5728(16)30355.
    PubMed     Text format     Abstract available


    December 2016
  133. ALVARENGA-FILHO H, Salles M, Hygino J, Ferreira TB, et al
    Fatigue favors in vitro Th1 and Th17-like cell expansion and reduces corticoid sensitivity in MS patients.
    J Neuroimmunol. 2016 Dec 30. pii: S0165-5728(16)30393.
    PubMed     Text format     Abstract available


  134. ANNUNZIATA P, Cioni C, Mugnaini C, Corelli F, et al
    Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis.
    J Neuroimmunol. 2016 Dec 23. pii: S0165-5728(16)30274.
    PubMed     Text format     Abstract available


  135. PAOLICELLI D, Manni A, D'Onghia M, Direnzo V, et al
    Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients.
    J Neuroimmunol. 2016 Dec 21. pii: S0165-5728(16)30371.
    PubMed     Text format     Abstract available


  136. MATUTE-BLANCH C, Rio J, Villar LM, Midaglia L, et al
    Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.
    J Neuroimmunol. 2016 Dec 18. pii: S0165-5728(16)30310.
    PubMed     Text format     Abstract available


  137. VOLPE G, Bernstock JD, Peruzzotti-Jametti L, Pluchino S, et al
    Modulation of host immune responses following non-hematopoietic stem cell transplantation: Translational implications in progressive multiple sclerosis.
    J Neuroimmunol. 2016 Dec 15. pii: S0165-5728(16)30312.
    PubMed     Text format     Abstract available


  138. GORDON-LIPKIN E, Calabresi PA
    Optical coherence tomography: A quantitative tool to measure neurodegeneration and facilitate testing of novel treatments for tissue protection in multiple sclerosis.
    J Neuroimmunol. 2016 Dec 14. pii: S0165-5728(16)30447.
    PubMed     Text format     Abstract available


  139. HOSSAIN MJ, Tanasescu R, Gran B
    Innate immune regulation of autoimmunity in multiple sclerosis: Focus on the role of Toll-like receptor 2.
    J Neuroimmunol. 2016 Dec 13. pii: S0165-5728(16)30448.
    PubMed     Text format     Abstract available


  140. MOMCILOVIC M, Stamenkovic V, Jovanovic M, Andjus PR, et al
    Tenascin-C deficiency protects mice from experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016 Dec 7. pii: S0165-5728(16)30207.
    PubMed     Text format     Abstract available


    November 2016
  141. HAGHMORAD D, Mahmoudi MB, Salehipour Z, Jalayer Z, et al
    Hesperidin ameliorates immunological outcome and reduces neuroinflammation in the mouse model of multiple sclerosis.
    J Neuroimmunol. 2016 Nov 26. pii: S0165-5728(16)30423.
    PubMed     Text format     Abstract available


  142. PROKOPOVA B, Hlavacova N, Vlcek M, Penesova A, et al
    Early cognitive impairment along with decreased stress-induced BDNF in male and female patients with newly diagnosed multiple sclerosis.
    J Neuroimmunol. 2016 Nov 19. pii: S0165-5728(16)30241.
    PubMed     Text format     Abstract available


  143. ACHIRON A, Zilkha-Falb R, Mashiach R, Gurevich M, et al
    RAM-589.555 a new Polymerase-1 inhibitor as innovative targeted-treatment for multiple sclerosis.
    J Neuroimmunol. 2016 Nov 17. pii: S0165-5728(16)30209.
    PubMed     Text format     Abstract available


  144. KARAMPOOR S, Zahednasab H, Ramagopalan S, Mehrpour M, et al
    Angiogenic factors are associated with multiple sclerosis.
    J Neuroimmunol. 2016 Nov 17. pii: S0165-5728(16)30304.
    PubMed     Text format     Abstract available


  145. ZHANG Y, Liu G, Duan Y, Han X, et al
    Prevalence of Small Intestinal Bacterial Overgrowth in Multiple Sclerosis: a Case-Control Study from China.
    J Neuroimmunol. 2016 Nov 16. pii: S0165-5728(16)30187.
    PubMed     Text format     Abstract available


  146. HAITAO R, Yingmai Y, Yan H, Fei H, et al
    Chorea and parkinsonism associated with autoantibodies to IgLON5 and responsive to immunotherapy.
    J Neuroimmunol. 2016;300:9-10.
    PubMed     Text format     Abstract available


  147. MURIS AH, Smolders J, Rolf L, Thewissen M, et al
    Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study.
    J Neuroimmunol. 2016;300:47-56.
    PubMed     Text format     Abstract available


  148. DIAS-CARNEIRO RP, von Glehn F, Moraes AS, Boldrini VO, et al
    MRZH reaction increases sensitivity for intrathecal IgG synthesis in IgG Oligoclonal band negative Multiple Sclerosis patients.
    J Neuroimmunol. 2016;300:30-35.
    PubMed     Text format     Abstract available


  149. GUASP M, Sola-Valls N, Martinez-Hernandez E, Gil MP, et al
    Cerebellar ataxia and autoantibodies restricted to glutamic acid decarboxylase 67 (GAD67).
    J Neuroimmunol. 2016;300:15-17.
    PubMed     Text format     Abstract available


  150. KALINOWSKA-LYSZCZARZ A, Michalak S, Pawlak MA, Losy J, et al
    Serum sPECAM-1 and sVCAM-1 levels are associated with conversion to multiple sclerosis in patients with optic neuritis.
    J Neuroimmunol. 2016;300:11-14.
    PubMed     Text format     Abstract available


  151. COVACU R, Brundin L
    Endogenous spinal cord stem cells in multiple sclerosis and its animal model.
    J Neuroimmunol. 2016 Nov 15. pii: S0165-5728(16)30403.
    PubMed     Text format     Abstract available


  152. IWASA K, Furukawa Y, Yoshikawa H, Yamada M, et al
    Caveolin-3 is aberrantly expressed in skeletal muscle cells in myasthenia gravis.
    J Neuroimmunol. 2016 Nov 9. pii: S0165-5728(16)30378.
    PubMed     Text format     Abstract available


  153. LV Z, Shi Q, Huang W, Xing C, et al
    MicroRNA expression profiling in Guillain-Barre syndrome.
    J Neuroimmunol. 2016 Nov 4. pii: S0165-5728(16)30374.
    PubMed     Text format     Abstract available


  154. HAAS J, Schwarz A, Korporal-Kuhnke M, Jarius S, et al
    Myeloid dendritic cells exhibit defects in activation and function in patients with multiple sclerosis.
    J Neuroimmunol. 2016 Nov 2. pii: S0165-5728(16)30258.
    PubMed     Text format     Abstract available


  155. AHARONI R, Rosen C, Shezen E, Bar-Lev DD, et al
    Assessing remyelination - metabolic labeling of myelin in an animal model of multiple sclerosis.
    J Neuroimmunol. 2016 Nov 1. pii: S0165-5728(16)30381.
    PubMed     Text format     Abstract available


    October 2016
  156. SAMUKAWA M, Kuwahara M, Morikawa M, Ueno R, et al
    Electrophysiological assessment of Guillain-Barre syndrome with both Gal-C and ganglioside antibodies; tendency for demyelinating type.
    J Neuroimmunol. 2016 Oct 24. pii: S0165-5728(16)30348.
    PubMed     Text format     Abstract available


  157. MELIEF J, Koper JW, Endert E, Moller HJ, et al
    Glucocorticoid receptor haplotypes conferring increased sensitivity (BclI and N363S) are associated with faster progression of multiple sclerosis.
    J Neuroimmunol. 2016;299:84-89.
    PubMed     Text format     Abstract available


  158. FENOGLIO C, De Riz M, Pietroboni AM, Calvi A, et al
    Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis.
    J Neuroimmunol. 2016;299:81-83.
    PubMed     Text format     Abstract available


  159. DA COSTA DS, Hygino J, Ferreira TB, Kasahara TM, et al
    Vitamin D modulates different IL-17-secreting T cell subsets in multiple sclerosis patients.
    J Neuroimmunol. 2016;299:8-18.
    PubMed     Text format     Abstract available


  160. PULIDO MA, DerHartunian MK, Qin Z, Chung EM, et al
    Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity against neuronal protein ELAVL4.
    J Neuroimmunol. 2016;299:70-78.
    PubMed     Text format     Abstract available


  161. BETTINI M, Gonorazky H, Chaves M, Fulgenzi E, et al
    Immune-mediated rippling muscle disease and myasthenia gravis.
    J Neuroimmunol. 2016;299:59-61.
    PubMed     Text format     Abstract available


  162. BRIKEN S, Rosenkranz SC, Keminer O, Patra S, et al
    Effects of exercise on Irisin, BDNF and IL-6 serum levels in patients with progressive multiple sclerosis.
    J Neuroimmunol. 2016;299:53-58.
    PubMed     Text format     Abstract available


  163. WANG J, Zhao C, Kong P, Bian G, et al
    Methylene blue alleviates experimental autoimmune encephalomyelitis by modulating AMPK/SIRT1 signaling pathway and Th17/Treg immune response.
    J Neuroimmunol. 2016;299:45-52.
    PubMed     Text format     Abstract available


  164. JONS D, Kneider M, Fogelstrand L, Jeppsson A, et al
    Early hematopoiesis in multiple sclerosis patients.
    J Neuroimmunol. 2016;299:158-163.
    PubMed     Text format     Abstract available


  165. DOOLEY MM, de Gannes SL, Fu KA, Lindsey JW, et al
    The increased antibody response to Epstein-Barr virus in multiple sclerosis is restricted to selected virus proteins.
    J Neuroimmunol. 2016;299:147-151.
    PubMed     Text format     Abstract available


  166. WALLER R, Woodroofe MN, Wharton SB, Ince PG, et al
    Gene expression profiling of the astrocyte transcriptome in multiple sclerosis normal appearing white matter reveals a neuroprotective role.
    J Neuroimmunol. 2016;299:139-146.
    PubMed     Text format     Abstract available


  167. ZHANG F, Liu G, Bu Y, Ma X, et al
    Expression profile of long noncoding RNAs and mRNAs in peripheral blood mononuclear cells from myasthenia gravis patients.
    J Neuroimmunol. 2016;299:124-129.
    PubMed     Text format     Abstract available


  168. MANE-MARTINEZ MA, Olsson B, Bau L, Matas E, et al
    Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.
    J Neuroimmunol. 2016;299:112-117.
    PubMed     Text format     Abstract available


  169. LIM JA, Lee ST, Moon J, Jun JS, et al
    New feasible treatment for refractory autoimmune encephalitis: Low-dose interleukin-2.
    J Neuroimmunol. 2016;299:107-111.
    PubMed     Text format     Abstract available


  170. MAGGI P, Sati P, Massacesi L
    Magnetic resonance imaging of experimental autoimmune encephalomyelitis in the common marmoset.
    J Neuroimmunol. 2016 Oct 8. pii: S0165-5728(16)30306.
    PubMed     Text format     Abstract available


  171. CROSS AH, Song SK
    "A new imaging modality to non-invasively assess multiple sclerosis pathology".
    J Neuroimmunol. 2016 Oct 8. pii: S0165-5728(16)30328.
    PubMed     Text format     Abstract available


  172. REICH DS
    Imag(in)ing multiple sclerosis: Time to take better pictures.
    J Neuroimmunol. 2016 Oct 3. pii: S0165-5728(16)30307.
    PubMed     Text format     Abstract available


  173. ITOH N, Kim R, Peng M, DiFilippo E, et al
    Bedside to bench to bedside research: Estrogen receptor beta ligand as a candidate neuroprotective treatment for multiple sclerosis.
    J Neuroimmunol. 2016 Oct 3. pii: S0165-5728(16)30308.
    PubMed     Text format     Abstract available


    September 2016
  174. BOIOCCHI C, Monti MC, Osera C, Mallucci G, et al
    Heat shock protein 70-hom gene polymorphism and protein expression in multiple sclerosis.
    J Neuroimmunol. 2016;298:189-93.
    PubMed     Text format     Abstract available


  175. TAO Y, Zhang X, Markovic-Plese S
    Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS).
    J Neuroimmunol. 2016;298:181-8.
    PubMed     Text format     Abstract available


  176. DOURADO ME JUNIOR, Ferreira LC, Freire-Neto FP, Jeronimo SM, et al
    No association between FCGR2A and FCGR3A polymorphisms in Guillain-Barre Syndrome in a Brazilian population.
    J Neuroimmunol. 2016;298:160-4.
    PubMed     Text format     Abstract available


  177. MENG QF, Zhang Z, Wang YJ, Chen W, et al
    Astilbin ameliorates experimental autoimmune myasthenia gravis by decreased Th17 cytokines and up-regulated T regulatory cells.
    J Neuroimmunol. 2016;298:138-45.
    PubMed     Text format     Abstract available


  178. OZGUN-ACAR O, Celik-Turgut G, Gazioglu I, Kolak U, et al
    Capparis ovata treatment suppresses inflammatory cytokine expression and ameliorates experimental allergic encephalomyelitis model of multiple sclerosis in C57BL/6 mice.
    J Neuroimmunol. 2016;298:106-16.
    PubMed     Text format     Abstract available


  179. COSENTINO M, Zaffaroni M, Legnaro M, Bombelli R, et al
    Dopaminergic receptors and adrenoceptors in circulating lymphocytes as putative biomarkers for the early onset and progression of multiple sclerosis.
    J Neuroimmunol. 2016;298:82-9.
    PubMed     Text format     Abstract available


  180. LEBRUN C, Bourg V, Bresch S, Cohen M, et al
    Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis.
    J Neuroimmunol. 2016;298:79-81.
    PubMed     Text format     Abstract available


  181. KARNI A, Asmail A, Drory VE, Kolb H, et al
    Thymus involvement in myasthenia gravis: Epidemiological and clinical impacts of different self-tolerance breakdown mechanisms.
    J Neuroimmunol. 2016;298:58-62.
    PubMed     Text format     Abstract available


  182. HONG Y, Li HF, Skeie GO, Romi F, et al
    Autoantibody profile and clinical characteristics in a cohort of Chinese adult myasthenia gravis patients.
    J Neuroimmunol. 2016;298:51-7.
    PubMed     Text format     Abstract available


  183. HORSTMANN L, Kuehn S, Pedreiturria X, Haak K, et al
    Microglia response in retina and optic nerve in chronic experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016;298:32-41.
    PubMed     Text format     Abstract available


  184. MIYAZAKI Y, Niino M, Kanazawa I, Suzuki M, et al
    Fingolimod suppresses bone resorption in female patients with multiple sclerosis.
    J Neuroimmunol. 2016;298:24-31.
    PubMed     Text format     Abstract available


  185. EFTHYMIOU G, Dardiotis E, Liaskos C, Marou E, et al
    Anti-hsp60 antibody responses based on Helicobacter pylori in patients with multiple sclerosis: (ir)Relevance to disease pathogenesis.
    J Neuroimmunol. 2016;298:19-23.
    PubMed     Text format     Abstract available


  186. TANAKA M, Tanaka K
    Sudden hearing loss as the initial symptom in Japanese patients with multiple sclerosis and seropositive neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2016;298:16-8.
    PubMed     Text format     Abstract available


  187. BERG J, Mahmoudjanlou Y, Duscha A, Massa MG, et al
    The immunomodulatory effect of laquinimod in CNS autoimmunity is mediated by the aryl hydrocarbon receptor.
    J Neuroimmunol. 2016;298:9-15.
    PubMed     Text format     Abstract available


    August 2016
  188. ZHANG Y, Liu G, Han X, Dong H, et al
    The association of serum 25-hydroxyvitamin D levels with multiple sclerosis severity and progression in a case-control study from China.
    J Neuroimmunol. 2016;297:127-31.
    PubMed     Text format     Abstract available


  189. KEIL M, Sonner JK, Lanz TV, Oezen I, et al
    General control non-derepressible 2 (GCN2) in T cells controls disease progression of autoimmune neuroinflammation.
    J Neuroimmunol. 2016;297:117-26.
    PubMed     Text format     Abstract available


  190. PUTHENPARAMPIL M, Miante S, Federle L, Zanetta C, et al
    BAFF is decreased in the cerebrospinal fluid of multiple sclerosis at clinical onset.
    J Neuroimmunol. 2016;297:63-7.
    PubMed     Text format     Abstract available


  191. SHENG JR, Rezania K, Soliven B
    Impaired regulatory B cells in myasthenia gravis.
    J Neuroimmunol. 2016;297:38-45.
    PubMed     Text format     Abstract available


  192. CALA CM, Moseley CE, Steele C, Dowdy SM, et al
    T cell cytokine signatures: Biomarkers in pediatric multiple sclerosis.
    J Neuroimmunol. 2016;297:1-8.
    PubMed     Text format     Abstract available


  193. LOVETT-RACKE AE
    Contribution of EAE to understanding and treating multiple sclerosis.
    J Neuroimmunol. 2016 Aug 12. pii: S0165-5728(16)30195.
    PubMed     Text format     Abstract available


    July 2016
  194. RACKE MK
    Therapeutic developments for autoimmune demyelinating diseases: Musing from an MD (mouse doctor).
    J Neuroimmunol. 2016 Jul 20. pii: S0165-5728(16)30157.
    PubMed     Text format     Abstract available


  195. LEVIN MC, Lee S, Gardner LA, Shin Y, et al
    Autoantibodies to heterogeneous nuclear ribonuclear protein A1 (hnRNPA1) cause altered 'ribostasis' and neurodegeneration; the legacy of HAM/TSP as a model of progressive multiple sclerosis.
    J Neuroimmunol. 2016 Jul 17. pii: S0165-5728(16)30155.
    PubMed     Text format     Abstract available


  196. NIMMAGADDA VK, Makar TK, Chandrasekaran K, Sagi AR, et al
    SIRT1 and NAD+ precursors: Therapeutic targets in multiple sclerosis a review.
    J Neuroimmunol. 2016 Jul 17. pii: S0165-5728(16)30158.
    PubMed     Text format     Abstract available


  197. VALENZUELA RM, Kaufman M, Balashov KE, Ito K, et al
    Predictive cytokine biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis.
    J Neuroimmunol. 2016 Jul 2. pii: S0165-5728(16)30137.
    PubMed     Text format     Abstract available


    June 2016
  198. MOHAMMADI N, Adib M, Alsahebfosoul F, Kazemi M, et al
    Corrigendum to "An investigation into the association between HLA-G 14bp insertion/deletion polymorphism and multiple sclerosis susceptibility" [Journal of Neuroimmunology 290 (2016) 115-118].
    J Neuroimmunol. 2016;295-296:164.
    PubMed     Text format    


  199. FAGONE P, Mangano K, Di Marco R, Touil-Boukoffa C, et al
    Corrigendum to "Expression of DNA methylation genes in secondary progressive multiple sclerosis" [J. Neuroimmunol. 290 (2016 Jan. 15) 66-9].
    J Neuroimmunol. 2016;295-296:163.
    PubMed     Text format    


  200. HUANG Q, Xiao B, Ma X, Qu M, et al
    MicroRNAs associated with the pathogenesis of multiple sclerosis.
    J Neuroimmunol. 2016;295-296:148-61.
    PubMed     Text format     Abstract available


  201. ANSARI QESHMI S, Dabbagh F, Borhani Haghighi A, Ghasemi Y, et al
    Bioinformatics evaluation of the possibility of heat shock proteins as autoantigens in multiple sclerosis based on molecular mimicry hypothesis.
    J Neuroimmunol. 2016;295-296:100-21.
    PubMed     Text format     Abstract available


  202. KUCUKERDEN M, Huda R, Tuzun E, Yilmaz A, et al
    MuSK induced experimental autoimmune myasthenia gravis does not require IgG1 antibody to MuSK.
    J Neuroimmunol. 2016;295-296:84-92.
    PubMed     Text format     Abstract available


  203. NAKANE S, Higuchi O, Hamada Y, Maeda Y, et al
    Ganglionic acetylcholine receptor autoantibodies in patients with Guillain-Barre syndrome.
    J Neuroimmunol. 2016;295-296:54-9.
    PubMed     Text format     Abstract available


  204. CHEN Y, Xing XW, Zhang JT, Wang RX, et al
    Autoimmune encephalitis mimicking sporadic Creutzfeldt-Jakob disease: A retrospective study.
    J Neuroimmunol. 2016;295-296:1-8.
    PubMed     Text format     Abstract available


    May 2016
  205. RAINE CS
    Multiple sclerosis: The resolving lesion revealed.
    J Neuroimmunol. 2016 May 27. pii: S0165-5728(16)30129.
    PubMed     Text format     Abstract available


  206. CATANZARO G, Pucci M, Viscomi MT, Lanuti M, et al
    Epigenetic modifications of Dexras 1 along the nNOS pathway in an animal model of multiple sclerosis.
    J Neuroimmunol. 2016;294:32-40.
    PubMed     Text format     Abstract available


  207. HAAS J, Schwarz A, Korporal-Kuhnke M, Faller S, et al
    Hypovitaminosis D upscales B-cell immunoreactivity in multiple sclerosis.
    J Neuroimmunol. 2016;294:18-26.
    PubMed     Text format     Abstract available


  208. ERDUR H, Scholz V, Streitz M, Hammer M, et al
    EBNA1 antigen-specific CD8+ T cells in cerebrospinal fluid of patients with multiple sclerosis.
    J Neuroimmunol. 2016;294:14-7.
    PubMed     Text format     Abstract available


  209. ZHAO M, Liu MD, Pu YY, Wang D, et al
    Hydrogen-rich water improves neurological functional recovery in experimental autoimmune encephalomyelitis mice.
    J Neuroimmunol. 2016;294:6-13.
    PubMed     Text format     Abstract available


  210. RIZZO R, Bortolotti D, Fainardi E, Gentili V, et al
    KIR2DL2 inhibitory pathway enhances Th17 cytokine secretion by NK cells in response to herpesvirus infection in multiple sclerosis patients.
    J Neuroimmunol. 2016;294:1-5.
    PubMed     Text format     Abstract available


  211. SINGH D, Torbey MT, Schwab JM
    Modifiable denominators of evolving post-stroke-autoimmunity.
    J Neuroimmunol. 2016 May 13. pii: S0165-5728(16)30106.
    PubMed     Text format    


    April 2016
  212. ZHANG M, Li XL, Li H, Wang S, et al
    Activation of the adenosine A2A receptor exacerbates experimental autoimmune neuritis in Lewis rats in association with enhanced humoral immunity.
    J Neuroimmunol. 2016;293:129-36.
    PubMed     Text format     Abstract available


  213. ALVARENGA-FILHO H, Sacramento PM, Ferreira TB, Hygino J, et al
    Combined exercise training reduces fatigue and modulates the cytokine profile of T-cells from multiple sclerosis patients in response to neuromediators.
    J Neuroimmunol. 2016;293:91-9.
    PubMed     Text format     Abstract available


  214. RAE W, Burke G, Pinto A
    A study of the utility of azathioprine metabolite testing in myasthenia gravis.
    J Neuroimmunol. 2016;293:82-5.
    PubMed     Text format     Abstract available


  215. YAMOUT B, Karaky NM, Mahfouz RA, Jaber F, et al
    Vitamin D receptor biochemical and genetic profiling and HLA-class II genotyping among Lebanese with multiple sclerosis - A pilot study.
    J Neuroimmunol. 2016;293:59-64.
    PubMed     Text format     Abstract available


  216. BENEDEK G, Zhang J, Bodhankar S, Nguyen H, et al
    Estrogen induces multiple regulatory B cell subtypes and promotes M2 microglia and neuroprotection during experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016;293:45-53.
    PubMed     Text format     Abstract available


  217. YANG B, Lian Y, Liu Y, Wu BY, et al
    A retrospective analysis of possible triggers of Guillain-Barre syndrome.
    J Neuroimmunol. 2016;293:17-21.
    PubMed     Text format     Abstract available


  218. ZHANG DQ, Jia K, Wang R, Li T, et al
    Decreased serum IL-27 and IL-35 levels are associated with disease severity in neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2016;293:100-4.
    PubMed     Text format     Abstract available


  219. BRILL L, Mandel M, Karussis D, Petrou P, et al
    Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel.
    J Neuroimmunol. 2016;293:65-70.
    PubMed     Text format     Abstract available


  220. SHI Z, Chen H, Lian Z, Liu J, et al
    Factors that impact health-related quality of life in neuromyelitis optica spectrum disorder: anxiety, disability, fatigue and depression.
    J Neuroimmunol. 2016;293:54-8.
    PubMed     Text format     Abstract available


  221. AKAISHI T, Nakashima I, Takeshita T, Mugikura S, et al
    Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica.
    J Neuroimmunol. 2016;293:28-33.
    PubMed     Text format     Abstract available


    March 2016
  222. STERGIOU C, Lazaridis K, Zouvelou V, Tzartos J, et al
    Titin antibodies in "seronegative" myasthenia gravis - A new role for an old antigen.
    J Neuroimmunol. 2016;292:108-15.
    PubMed     Text format     Abstract available


  223. MELNIKOV M, Belousova O, Murugin V, Pashenkov capital EM, Cyrillic, et al
    The role of dopamine in modulation of Th-17 immune response in multiple sclerosis.
    J Neuroimmunol. 2016;292:97-101.
    PubMed     Text format     Abstract available


  224. PATIL SA, Bokoliya SC, Nagappa M, Taly AB, et al
    Diagnosis of myasthenia gravis: Comparison of anti-nicotinic acetyl choline receptor antibodies, repetitive nerve stimulation and Neostigmine tests at a tertiary neuro care centre in India, a ten year study.
    J Neuroimmunol. 2016;292:81-4.
    PubMed     Text format     Abstract available


  225. SMOLDERS J, Muris AH, Damoiseaux J
    Immunomodulation by vitamin D in multiple sclerosis: More than IL-17.
    J Neuroimmunol. 2016;292:79-80.
    PubMed     Text format    


  226. MAGNER WJ, Weinstock-Guttman B, Rho M, Hojnacki D, et al
    Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.
    J Neuroimmunol. 2016;292:68-78.
    PubMed     Text format     Abstract available


  227. SUN Y, Tian T, Gao J, Liu X, et al
    Metformin ameliorates the development of experimental autoimmune encephalomyelitis by regulating T helper 17 and regulatory T cells in mice.
    J Neuroimmunol. 2016;292:58-67.
    PubMed     Text format     Abstract available


  228. BURMAN J, Raininko R, Blennow K, Zetterberg H, et al
    YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2016;292:52-7.
    PubMed     Text format     Abstract available


  229. BURMAN J, Svenningsson A
    Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2016;292:40-4.
    PubMed     Text format     Abstract available


  230. MARTIRE S, Navone ND, Montarolo F, Perga S, et al
    A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients.
    J Neuroimmunol. 2016;292:34-9.
    PubMed     Text format     Abstract available


  231. PUNGA T, Bartoccioni E, Lewandowska M, Damato V, et al
    Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis.
    J Neuroimmunol. 2016;292:21-6.
    PubMed     Text format     Abstract available


  232. MAKAR TK, Nimmagadda VK, Singh IS, Lam K, et al
    TrkB agonist, 7,8-dihydroxyflavone, reduces the clinical and pathological severity of a murine model of multiple sclerosis.
    J Neuroimmunol. 2016;292:9-20.
    PubMed     Text format     Abstract available


  233. MAUSNER-FAINBERG K, Kolb H, Penn M, Regev K, et al
    Differential screening-selected gene aberrative in neuroblastoma (DAN) is increased in the CSF of patients with MS and may be induced by therapy with interferon-beta.
    J Neuroimmunol. 2016;292:93-6.
    PubMed     Text format     Abstract available


    February 2016
  234. FATEMI I, Shamsizadeh A, Ayoobi F, Taghipour Z, et al
    Role of orexin-A in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016;291:101-9.
    PubMed     Text format     Abstract available


  235. HUIJBERS MG, Vink AF, Niks EH, Westhuis RH, et al
    Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity.
    J Neuroimmunol. 2016;291:82-8.
    PubMed     Text format     Abstract available


  236. MIYAJI K, Paul F, Shahrizaila N, Umapathi T, et al
    Autoantibodies to tetraspanins (CD9, CD81 and CD82) in demyelinating diseases.
    J Neuroimmunol. 2016;291:78-81.
    PubMed     Text format     Abstract available


  237. MATAS E, Bau L, Martinez-Iniesta M, Romero-Pinel L, et al
    MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients.
    J Neuroimmunol. 2016;291:73-7.
    PubMed     Text format     Abstract available


  238. FORWELL AL, Bernales CQ, Ross JP, Yee IM, et al
    Analysis of CH25H in multiple sclerosis and neuromyelitis optica.
    J Neuroimmunol. 2016;291:70-2.
    PubMed     Text format     Abstract available


  239. XIE C, Ciric B, Yu S, Zhang GX, et al
    IL-12Rbeta2 has a protective role in relapsing-remitting experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016;291:59-69.
    PubMed     Text format     Abstract available


  240. MORIGUCHI K, Miyamoto K, Tanaka N, Ueno R, et al
    C-C chemokine receptor type 4 antagonist Compound 22 ameliorates experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016;291:54-8.
    PubMed     Text format     Abstract available


  241. IRELAND SJ, Guzman AA, Frohman EM, Monson NL, et al
    B cells from relapsing remitting multiple sclerosis patients support neuro-antigen-specific Th17 responses.
    J Neuroimmunol. 2016;291:46-53.
    PubMed     Text format     Abstract available


  242. SHINODA K, Sun X, Oyamada A, Yamada H, et al
    Requirement of CD30 expression on CD4 T cells in the pathogenesis of experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016;291:39-45.
    PubMed     Text format     Abstract available


  243. MADEIRA A, Burgelin I, Perron H, Curtin F, et al
    MSRV envelope protein is a potent, endogenous and pathogenic agonist of human toll-like receptor 4: Relevance of GNbAC1 in multiple sclerosis treatment.
    J Neuroimmunol. 2016;291:29-38.
    PubMed     Text format     Abstract available


  244. ZAHEDNASAB H, Karampoor S
    The correlation of HLA-G with multiple sclerosis.
    J Neuroimmunol. 2016;291:28.
    PubMed     Text format    


  245. BLAIR TC, Manoharan M, Rawlings-Rhea SD, Tagge I, et al
    Immunopathology of Japanese macaque encephalomyelitis is similar to multiple sclerosis.
    J Neuroimmunol. 2016;291:1-10.
    PubMed     Text format     Abstract available


  246. ZHANG W, Jiao Y, Cui L, Jiao J, et al
    Differentiation of neuromyelitis optica spectrum disorders from ultra-longitudinally extensive transverse myelitis in a cohort of Chinese patients.
    J Neuroimmunol. 2016;291:96-100.
    PubMed     Text format     Abstract available


    January 2016
  247. MOHAMMADI N, Adib M, Alsahebfosoul F, Kazemi M, et al
    An investigation into the association between HLA-G 14bp insertion/deletion polymorphism and multiple sclerosis susceptibility.
    J Neuroimmunol. 2016;290:115-8.
    PubMed     Text format     Abstract available


  248. KHORRAMDELAZAD H, Bagheri V, Hassanshahi G, Zeinali M, et al
    New insights into the role of stromal cell-derived factor 1 (SDF-1/CXCL12) in the pathophysiology of multiple sclerosis.
    J Neuroimmunol. 2016;290:70-5.
    PubMed     Text format     Abstract available


  249. FAGONE P, Mangano K, Di Marco R, Touil-Boukoffa C, et al
    Expression of DNA methylation genes in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2016;290:66-9.
    PubMed     Text format     Abstract available


  250. ARUMUGAM M, Parthasarathy V
    Reduction of CD4(+)CD25(+) regulatory T-cells in migraine: Is migraine an autoimmune disorder?
    J Neuroimmunol. 2016;290:54-9.
    PubMed     Text format     Abstract available


  251. KARAMPOOR S, Zahednasab H, Ramagopalan S, Mehrpour M, et al
    25-hydroxyvitamin D levels are associated with multiple sclerosis in Iran: A cross-sectional study.
    J Neuroimmunol. 2016;290:47-8.
    PubMed     Text format     Abstract available


  252. MORENO MA, Burns T, Yao P, Miers L, et al
    Therapeutic depletion of monocyte-derived cells protects from long-term axonal loss in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016;290:36-46.
    PubMed     Text format     Abstract available


  253. FISCHER HJ, van den Brandt J, Lingner T, Odoardi F, et al
    Modulation of CNS autoimmune responses by CD8(+) T cells coincides with their oligoclonal expansion.
    J Neuroimmunol. 2016;290:26-32.
    PubMed     Text format     Abstract available


  254. SUNWOO JS, Chu K, Byun JI, Moon J, et al
    Intrathecal-specific glutamic acid decarboxylase antibodies at low titers in autoimmune neurological disorders.
    J Neuroimmunol. 2016;290:15-21.
    PubMed     Text format     Abstract available


  255. HASSON T, Kolitz S, Towfic F, Laifenfeld D, et al
    Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition.
    J Neuroimmunol. 2016;290:84-95.
    PubMed     Text format     Abstract available


  256. MAURER MA, Tuller F, Gredler V, Berger T, et al
    Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination.
    J Neuroimmunol. 2016;290:49-53.
    PubMed     Text format     Abstract available


    December 2015
  257. SUAREZ-CALVET X, Gallardo E, Illa I
    Comment to "Role of Toll-like receptors and retinoic acid inducible gene I in endogenous production of type I interferon in dermatomyositis".
    J Neuroimmunol. 2015 Dec 18. pii: S0165-5728(15)30101.
    PubMed     Text format    


  258. FUHLHUBER V, Bick S, Tschernatsch M, Dharmalingam B, et al
    Autoantibody-mediated cytotoxicity in paediatric opsoclonus-myoclonus syndrome is dependent on ERK-1/2 phophorylation.
    J Neuroimmunol. 2015;289:182-6.
    PubMed     Text format     Abstract available


  259. LEE CY, Lam CL, Pang SY, Lau KK, et al
    Clinical outcome of generalized myasthenia gravis in Hong Kong Chinese.
    J Neuroimmunol. 2015;289:177-81.
    PubMed     Text format     Abstract available


  260. LOSHAJ-SHALA A, Regazzoni L, Daci A, Orioli M, et al
    Guillain Barre syndrome (GBS): new insights in the molecular mimicry between C. jejuni and human peripheral nerve (HPN) proteins.
    J Neuroimmunol. 2015;289:168-76.
    PubMed     Text format     Abstract available


  261. SHENG JR, Quan S, Soliven B
    IL-10 derived from CD1d(hi)CD5(+) B cells regulates experimental autoimmune myasthenia gravis.
    J Neuroimmunol. 2015;289:130-8.
    PubMed     Text format     Abstract available


  262. MOHAJERI M, Sadeghizadeh M, Javan M
    Pertussis toxin promotes relapsing-remitting experimental autoimmune encephalomyelitis in Lewis rats.
    J Neuroimmunol. 2015;289:105-10.
    PubMed     Text format     Abstract available


  263. CHAUDHARY P, Marracci G, Galipeau D, Pocius E, et al
    Lipoic acid reduces inflammation in a mouse focal cortical experimental autoimmune encephalomyelitis model.
    J Neuroimmunol. 2015;289:68-74.
    PubMed     Text format     Abstract available


  264. ALEXOPOULOS H, Kampylafka EI, Fouka P, Tatouli I, et al
    Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease.
    J Neuroimmunol. 2015;289:8-11.
    PubMed     Text format     Abstract available


  265. HORELLOU P, Wang M, Keo V, Chretien P, et al
    Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis.
    J Neuroimmunol. 2015;289:1-7.
    PubMed     Text format     Abstract available


  266. SIUKO M, Valori M, Kivela T, Setala K, et al
    Exome and regulatory element sequencing of neuromyelitis optica patients.
    J Neuroimmunol. 2015;289:139-42.
    PubMed     Text format     Abstract available


  267. YAMOUT BI, Zeineddine MM, Tamim H, Khoury SJ, et al
    Safety and efficacy of fingolimod in clinical practice: The experience of an academic center in the Middle East.
    J Neuroimmunol. 2015;289:93-7.
    PubMed     Text format     Abstract available


  268. KANG H, Cao S, Chen T, Jiang Z, et al
    The poor recovery of neuromyelitis optica spectrum disorder is associated with a lower level of CXCL12 in the human brain.
    J Neuroimmunol. 2015;289:56-61.
    PubMed     Text format     Abstract available


    November 2015
  269. TANAKA M, Kinoshita M
    Daily fingolimod administration may cause lymphopenia but alternate-day administration may be too little to inhibit disease activity.
    J Neuroimmunol. 2015;288:69.
    PubMed     Text format     Abstract available


  270. ARVIDSSON L, Covacu R, Estrada CP, Sankavaram SR, et al
    Long-distance effects of inflammation on differentiation of adult spinal cord neural stem/progenitor cells.
    J Neuroimmunol. 2015;288:47-55.
    PubMed     Text format     Abstract available


  271. RAMIREZ GA, Lanzani C, Bozzolo EP, Citterio L, et al
    TRPC6 gene variants and neuropsychiatric lupus.
    J Neuroimmunol. 2015;288:21-4.
    PubMed     Text format     Abstract available


    October 2015
  272. MEALY MA, Levy M
    Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab.
    J Neuroimmunol. 2015;287:29-30.
    PubMed     Text format     Abstract available


  273. KON T, Nishijima H, Haga R, Funamizu Y, et al
    Hypertrophic pachymeningitis accompanying neuromyelitis optica spectrum disorder: A case report.
    J Neuroimmunol. 2015;287:27-8.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: